Management Strategies for CLN2 Disease

Ruth E. Williams, Heather R. Adams, Martin Blohm, Jessica L. Cohen-Pfeffer, Emily de los Reyes, Jonas Denecke, Kristen Drago, Charlie Fairhurst, Margie Frazier, Norberto Guelbert, Szilárd Kiss, Annamaria Kofler, John A. Lawson, Lenora Lehwald, Mary Anne Leung, Svetlana Mikhaylova, Jonathan W. Mink, Miriam Nickel, Renée Shediac, Katherine SimsNicola Specchio, Meral Topcu, Ina von Löbbecke, Andrea West, Boris Zernikow, Angela Schulz

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death. No management guidelines exist and there is a paucity of published disease-specific evidence to inform clinical practice, which currently draws upon experience from the field of childhood neurodisability. Twenty-four disease experts were surveyed on CLN2 disease management and a subset met to discuss current practice. Management goals and strategies are consistent among experts globally and are guided by the principles of pediatric palliative care. Goals and interventions evolve as the disease progresses, with a shift in focus from maintenance of function early in the disease to maintenance of quality of life. A multidisciplinary approach is critical for optimal patient care. This work represents an initial step toward the development of consensus-based management guidelines for CLN2 disease.

Original languageEnglish
Pages (from-to)102-112
Number of pages11
JournalPediatric Neurology
Volume69
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Guidelines
Pediatrics
Language Development Disorders
Blindness
Disease Management
Palliative Care
Consensus
Patient Care
Seizures
Maintenance
Quality of Life
Enzymes
Cognitive Dysfunction
tripeptidyl-peptidase 1
Ceroid Lipofuscinosis, Neuronal, 2

Keywords

  • CLN2 disease
  • consensus
  • late-infantile Batten disease
  • late-infantile neuronal ceroid lipofuscinosis
  • management
  • neuronal ceroid lipofuscinosis type 2
  • palliative care

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Williams, R. E., Adams, H. R., Blohm, M., Cohen-Pfeffer, J. L., de los Reyes, E., Denecke, J., ... Schulz, A. (2017). Management Strategies for CLN2 Disease. Pediatric Neurology, 69, 102-112. https://doi.org/10.1016/j.pediatrneurol.2017.01.034

Management Strategies for CLN2 Disease. / Williams, Ruth E.; Adams, Heather R.; Blohm, Martin; Cohen-Pfeffer, Jessica L.; de los Reyes, Emily; Denecke, Jonas; Drago, Kristen; Fairhurst, Charlie; Frazier, Margie; Guelbert, Norberto; Kiss, Szilárd; Kofler, Annamaria; Lawson, John A.; Lehwald, Lenora; Leung, Mary Anne; Mikhaylova, Svetlana; Mink, Jonathan W.; Nickel, Miriam; Shediac, Renée; Sims, Katherine; Specchio, Nicola; Topcu, Meral; von Löbbecke, Ina; West, Andrea; Zernikow, Boris; Schulz, Angela.

In: Pediatric Neurology, Vol. 69, 01.04.2017, p. 102-112.

Research output: Contribution to journalReview article

Williams, RE, Adams, HR, Blohm, M, Cohen-Pfeffer, JL, de los Reyes, E, Denecke, J, Drago, K, Fairhurst, C, Frazier, M, Guelbert, N, Kiss, S, Kofler, A, Lawson, JA, Lehwald, L, Leung, MA, Mikhaylova, S, Mink, JW, Nickel, M, Shediac, R, Sims, K, Specchio, N, Topcu, M, von Löbbecke, I, West, A, Zernikow, B & Schulz, A 2017, 'Management Strategies for CLN2 Disease', Pediatric Neurology, vol. 69, pp. 102-112. https://doi.org/10.1016/j.pediatrneurol.2017.01.034
Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de los Reyes E, Denecke J et al. Management Strategies for CLN2 Disease. Pediatric Neurology. 2017 Apr 1;69:102-112. https://doi.org/10.1016/j.pediatrneurol.2017.01.034
Williams, Ruth E. ; Adams, Heather R. ; Blohm, Martin ; Cohen-Pfeffer, Jessica L. ; de los Reyes, Emily ; Denecke, Jonas ; Drago, Kristen ; Fairhurst, Charlie ; Frazier, Margie ; Guelbert, Norberto ; Kiss, Szilárd ; Kofler, Annamaria ; Lawson, John A. ; Lehwald, Lenora ; Leung, Mary Anne ; Mikhaylova, Svetlana ; Mink, Jonathan W. ; Nickel, Miriam ; Shediac, Renée ; Sims, Katherine ; Specchio, Nicola ; Topcu, Meral ; von Löbbecke, Ina ; West, Andrea ; Zernikow, Boris ; Schulz, Angela. / Management Strategies for CLN2 Disease. In: Pediatric Neurology. 2017 ; Vol. 69. pp. 102-112.
@article{d9eaa01d6af145c3982c1d62238a0f3a,
title = "Management Strategies for CLN2 Disease",
abstract = "CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death. No management guidelines exist and there is a paucity of published disease-specific evidence to inform clinical practice, which currently draws upon experience from the field of childhood neurodisability. Twenty-four disease experts were surveyed on CLN2 disease management and a subset met to discuss current practice. Management goals and strategies are consistent among experts globally and are guided by the principles of pediatric palliative care. Goals and interventions evolve as the disease progresses, with a shift in focus from maintenance of function early in the disease to maintenance of quality of life. A multidisciplinary approach is critical for optimal patient care. This work represents an initial step toward the development of consensus-based management guidelines for CLN2 disease.",
keywords = "CLN2 disease, consensus, late-infantile Batten disease, late-infantile neuronal ceroid lipofuscinosis, management, neuronal ceroid lipofuscinosis type 2, palliative care",
author = "Williams, {Ruth E.} and Adams, {Heather R.} and Martin Blohm and Cohen-Pfeffer, {Jessica L.} and {de los Reyes}, Emily and Jonas Denecke and Kristen Drago and Charlie Fairhurst and Margie Frazier and Norberto Guelbert and Szil{\'a}rd Kiss and Annamaria Kofler and Lawson, {John A.} and Lenora Lehwald and Leung, {Mary Anne} and Svetlana Mikhaylova and Mink, {Jonathan W.} and Miriam Nickel and Ren{\'e}e Shediac and Katherine Sims and Nicola Specchio and Meral Topcu and {von L{\"o}bbecke}, Ina and Andrea West and Boris Zernikow and Angela Schulz",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.pediatrneurol.2017.01.034",
language = "English",
volume = "69",
pages = "102--112",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Management Strategies for CLN2 Disease

AU - Williams, Ruth E.

AU - Adams, Heather R.

AU - Blohm, Martin

AU - Cohen-Pfeffer, Jessica L.

AU - de los Reyes, Emily

AU - Denecke, Jonas

AU - Drago, Kristen

AU - Fairhurst, Charlie

AU - Frazier, Margie

AU - Guelbert, Norberto

AU - Kiss, Szilárd

AU - Kofler, Annamaria

AU - Lawson, John A.

AU - Lehwald, Lenora

AU - Leung, Mary Anne

AU - Mikhaylova, Svetlana

AU - Mink, Jonathan W.

AU - Nickel, Miriam

AU - Shediac, Renée

AU - Sims, Katherine

AU - Specchio, Nicola

AU - Topcu, Meral

AU - von Löbbecke, Ina

AU - West, Andrea

AU - Zernikow, Boris

AU - Schulz, Angela

PY - 2017/4/1

Y1 - 2017/4/1

N2 - CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death. No management guidelines exist and there is a paucity of published disease-specific evidence to inform clinical practice, which currently draws upon experience from the field of childhood neurodisability. Twenty-four disease experts were surveyed on CLN2 disease management and a subset met to discuss current practice. Management goals and strategies are consistent among experts globally and are guided by the principles of pediatric palliative care. Goals and interventions evolve as the disease progresses, with a shift in focus from maintenance of function early in the disease to maintenance of quality of life. A multidisciplinary approach is critical for optimal patient care. This work represents an initial step toward the development of consensus-based management guidelines for CLN2 disease.

AB - CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death. No management guidelines exist and there is a paucity of published disease-specific evidence to inform clinical practice, which currently draws upon experience from the field of childhood neurodisability. Twenty-four disease experts were surveyed on CLN2 disease management and a subset met to discuss current practice. Management goals and strategies are consistent among experts globally and are guided by the principles of pediatric palliative care. Goals and interventions evolve as the disease progresses, with a shift in focus from maintenance of function early in the disease to maintenance of quality of life. A multidisciplinary approach is critical for optimal patient care. This work represents an initial step toward the development of consensus-based management guidelines for CLN2 disease.

KW - CLN2 disease

KW - consensus

KW - late-infantile Batten disease

KW - late-infantile neuronal ceroid lipofuscinosis

KW - management

KW - neuronal ceroid lipofuscinosis type 2

KW - palliative care

UR - http://www.scopus.com/inward/record.url?scp=85016044339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016044339&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2017.01.034

DO - 10.1016/j.pediatrneurol.2017.01.034

M3 - Review article

C2 - 28335910

AN - SCOPUS:85016044339

VL - 69

SP - 102

EP - 112

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

ER -